AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie synagis (palivizumab) — International net revenues [legacy through FY20Q1] ($M) ($M)
Form 10-Q / 10-K Segment Note
Latest, FY2019
718
Period ended Dec 31, 2019
Change on a year earlier
-1.1%
726 in FY2018
History
4 years
Since FY2016
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Synagis (palivizumab) — International net revenues [legacy through FY20Q1] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2019 | Dec 31, 2019 | 718 | -1.1% | Form 10-K (filed 2020-02-21) ↗ |
| FY2018 | Dec 31, 2018 | 726 | -1.6% | Form 10-K (filed 2020-02-21) ↗ |
| FY2017 | Dec 31, 2017 | 738 | +1.1% | Form 10-K (filed 2020-02-21) ↗ |
| FY2016 | Dec 31, 2016 | 730 | – | Form 10-K (filed 2019-02-27) ↗ |
Cite this data
StockData. (2026). AbbVie Synagis (palivizumab) — International net revenues [legacy through FY20Q1] ($M) ($M), annual FY2016–FY2019 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/synagis_intl
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.